This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe
27 - 29 May, 2026
Congress CenterBasel Switzerland

Dr. Monika Semmrich, PhD
Principal Scientist, Preclinical Research at BioInvent International AB
Speaker

Profile

Monika is an immunologist with a PhD from the Technical University in Munich. After receiving her PhD, she went on to a postdoc at the Immunology Department in Lund (Sweden), focusing on the characterization of intestinal cell subsets. In 2012, Monika joined BioInvent International AB, a company developing antibodies for the treatment of cancer using BioInvent’s F.I.R.S.T platform. Currently, she holds a position as Principal Scientist where she applies her immunological expertise to support and manage several preclinical projects, from the early discovery phase through to clinical stage.

Agenda Sessions

  • A Function-First Approach to Identify Regulatory T Cell-Targeting Antibodies for Immunotherapy

    08:50